Mutations in the charged multivesicular body protein 2B (CHMP2B) gene cause frontotemporal lobar degeneration. The mutations lead to C-terminal truncation of the CHMP2B protein. We generated Chmp2b knockout mice and transgenic mice expressing either wild-type or C-terminally truncated mutant CHMP2B. The transgenic CHMP2B mutant mice have decreased survival and show progressive neurodegenerative changes including gliosis and increasing accumulation of p62-and ubiquitin-positive inclusions. The inclusions are negative for the TAR DNA binding protein 43 and fused in sarcoma proteins, mimicking the inclusions observed in patients with CHMP2B mutation. Mice transgenic for mutant CHMP2B also develop an early and progressive axonopathy characterized by numerous amyloid precursor protein-positive axonal swellings, implicating altered axonal function in disease pathogenesis. These findings were not observed in Chmp2b knockout mice or in transgenic mice expressing wild-type CHMP2B, indicating that CHMP2B mutations induce degenerative changes through a gain of function mechanism. These data describe the first mouse model of dementia caused by CHMP2B mutation and provide new insights into the mechanisms of CHMP2B-induced neurodegeneration.
Introduction
Frontotemporal lobar degeneration (FTLD) is the second most common form of young onset dementia after Alzheimer's disease (Ratnavalli et al., 2002; Harvey et al., 2003) . It can present with behavioural changes or with language impairment, dependent on which parts of the frontal and temporal lobes are affected, andmotor neuron disease (Neary et al., 1998; McKhann et al., 2001) . Mutations in the MAPT gene (Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998) encoding the tau protein, in the GRN gene (Baker et al., 2006; Cruts et al., 2006) encoding progranulin and in the C9ORF72 gene Renton et al., 2011) are the most common genetic causes of FTLD. Rare mutations have been identified in the valosin-containing protein (VCP), TARDBP (which encodes TDP-43), FUS (fused in sarcoma) and charged multivesicular body protein 2B (CHMP2B) genes (Watts et al., 2004; Skibinski et al., 2005; van der Zee et al., 2008; Benajiba et al., 2009; Borroni et al., 2009; Kovacs et al., 2009; Van Langenhove et al., 2010) . FTLD is characterized neuropathologically by the presence of either tau-or ubiquitin-positive intraneuronal inclusions (Cairns et al., 2007) . The ubiquitin-positive inclusions generally contain the ubiquitin binding protein p62 (Pikkarainen et al., 2008) and either TAR DNA binding protein 43 (TDP-43, the most common subtype) or FUS . CHMP2B mutation cases belong to a rare subtype that have ubiquitin-and p62-positive inclusions that are negative for both TDP-43 and FUS (Holm et al., 2007 (Holm et al., , 2009 ; Urwin et al., 2010b) .
CHMP2B is part of ESCRT-III (endosomal sorting complex required for transport-III), a multiprotein complex involved in endosomal and autophagic trafficking of proteins to lysosomes for degradation (Katzmann et al., 2002; Rusten and Stenmark, 2009 ). There is evidence that CHMP2B mutations can affect endosomal and autophagic trafficking (Filimonenko et al., 2007; Lee et al., 2007; Metcalf and Isaacs, 2010; Urwin et al., 2010a) , but the mechanisms that lead to neuronal cell death are unknown Urwin et al., 2009) .
The first CHMP2B mutation was identified in a large Danish FTLD family (Skibinski et al., 2005) and a second mutation was subsequently identified in a Belgian patient with familial FTLD (van der Zee et al., 2008) . The Danish mutation occurs in the acceptor splice site of the sixth and final CHMP2B exon, leading to the formation of two aberrant transcripts termed CHMP2B intron 5 and CHMP2B Á10 which both replace the final 36 amino acids of CHMP2B with novel C-termini due to mis-splicing (Skibinski et al., 2005) . The Belgian mutation is a truncation mutation that removes the final 48 amino acids, suggesting that loss of the C-terminus of CHMP2B may be a common mechanism by which these mutations lead to disease. However, both mutations also lead to the loss of one normal copy of CHMP2B, suggesting that loss of function could also play a role in disease pathogenesis.
To distinguish between these possibilities, and to generate the first mouse models of CHMP2B-induced FTLD, we generated Chmp2b knockout mice and transgenic mice expressing either CHMP2B wild-type or CHMP2B intron 5 , which is the mutant transcript expressed at the highest level in patient brains (Urwin et al., 2010a) . We provide evidence in favour of a gain of function mechanism in CHMP2B-induced FTLD by showing that neuropathology mimicking human patients are observed only in CHMP2B intron 5 mice and not in CHMP2B wild-type mice or
Chmp2b knockout mice. We also identify axonal changes as an early degenerative feature in CHMP2B intron 5 mice, suggesting a potential role for altered axonal function in the disease process.
Materials and methods
Generation of CHMP2B transgenic mice CHMP2B wild-type and CHMP2B intron 5 were polymerase chain reaction amplified from previously generated expression plasmids (Skibinski et al., 2005) (Scott et al., 1989) and preparation of high quality DNA of the insert was as previously reported (Asante et al., 2002) . The purified transgenes were microinjected into single cell eggs of (CBA Â C57BL/6) mice. The injected eggs were cultured to the 2-cell stage and then surgically transferred to F1 (CBA Â C57BL/6) recipient females. Tail biopsies were taken from putative transgenics and screened by polymerase chain reaction using human CHMP2B specific primers 5 0 -gtcgacaccatggcgtccctcttcaagaag-3 0 and 5 0 -ctcgagc taatctactcctaaagccttgag-3 0 . Founders were bred to non-transgenic C57BL/6 mice and transgene expression assessed by real time-polymerase chain reaction and confirmed by immunoblotting. Two CHMP2B intron 5 lines were generated, Tg153 and Tg156. The
Tg153 line was interbred to generate homozygous mice and was maintained as a homozygous line. Homozygous Tg153 mice were used for all experiments described unless otherwise stated. The Tg156 line would not breed as a homozygous line so was maintained as a hemizygous line by interbreeding and was used for confirmation of pathological findings ( Supplementary Fig. 1 ). Two CHMP2B wild-type lines were generated, Tg167 and Tg168, and were maintained as hemizygous lines by interbreeding. Non-transgenic littermates from both Tg167 and Tg168 matings were used as controls. The lower expressing line Tg168 was used for all experiments described unless otherwise stated and Tg167 used for confirmatory experiments.
Generation of Chmp2b knockout mice
An in silico search of the BayGenomics genetrap resource identified that embryonic stem cell line XL952 (genetic background 129P2/ OlaHsd) had a genetrap insertion (vector pGTOLxf) in intron 2 of Chmp2b (between exons 2 and 3). XL952 embryonic stem cells were injected into host blastocysts to generate chimeras. Two male chimeras predicted to be 490% chimeric based on coat colour were bred to C57BL/6J females and germline transmission confirmed. Sperm from the resulting F1 males was recovered and in vitro fertilization with C57BL/6J eggs was used to produce 2-cell embryos for shipment to the UK. Embryos were implanted into pseudopregnant females and the resulting mice interbred to generate homozygous knockouts. Sequencing identified the insertion site of the genetrap cassette to be 685 bp upstream of the beginning of intron 2.
Survival analysis
We analysed survival of our Chmp2b knockout colony (Chmp2b À / À n = 125, Chmp2b + / + n = 117), and CHMP2B transgenic lines Tg153
(n = 18), Tg168 (n = 16), and non-transgenics (n = 21). Kaplan-Meier survival analysis was performed using SPSS 15.0, and a Log Rank test used to determine significance.
Generation of CHMP2B antibodies
Ten rabbit polyclonal antisera against full length recombinant CHMP2B were generated by Biogenes and tested for immunoblotting and immunohistochemistry. The optimal antiserum for western blotting and immunohistochemistry were designated 3335 and 3371, respectively.
Quantification of RNA transcripts
RNA was extracted from frozen brain using TRIzol (Invitrogen), treated with TURBO DNase (Ambion) and purified using an RNeasy Mini Column (Qiagen). Complementary DNA was generated using the Omniscript Reverse Transcription Kit (Qiagen). CHMP2B RNA was quantified with real-time polymerase chain reaction using primers and a TaqMan Õ probe that detected both human and mouse CHMP2B (see Supplementary Table 1 for primer sequences). Total CHMP2B RNA levels for three mice per genotype at 6 months of age were compared after normalization to GAPDH.
Immunoblotting
Brain homogenates (10% w/v) were prepared in Dulbecco's phosphate-buffered saline lacking Ca 2 + or Mg 2 + ions (D-PBS) using a
RiboLyser homogenizer (Hybaid), boiled in the appropriate volume of 2 Â Laemmli sample buffer and run on 4-20% or 12% sodium dodecyl sulphate-polyacrylamide gel electrophoresis gels (Invitrogen), transferred onto polyvinylidene fluoride or nitrocellulose and probed with primary antibodies as follows: anti-CHMP2B 3335 (in-house rabbit polyclonal used for the detection of CHMP2B in the transgenic mouse lines) 1:2000; anti-CHMP2B C-terminus (ab33174, Abcam), 1:1000; anti-p62 (H00008878-MO1, Abnova) 1:40 000. Detection was performed with horseradish peroxidase-conjugated secondary antibodies and SuperSignal West Pico Chemiluminescent Substrate (Thermo scientific). Quantification was performed using Volocity software (Perkin Elmer), bands were normalized to actin and averages taken of three mice per genotype. For fractionation, 10% (w/v) brain homogenates were prepared in D-PBS and combined 1:1 with 2% sarkosyl (N-lauroylsarcosine) in D-PBS. Benzonase (50 U/ml; Novagen) were added to remove DNA and the homogenates incubated with constant agitation at 37 C for 30 min, followed by ultracentrifugation at 100 000 g for 30 min at 4 C. The supernatant was removed and saved as the soluble fraction. Pellets were washed in 1% sarkosyl in D-PBS and spun at 100 000 g for 30 min. The supernatant was discarded and the pellet solubilized in 4% sodium dodecyl sulphate, followed by the addition of 2 Â Laemmli sample buffer and heating at 100 C for 10 min prior to sodium dodecyl sulphate-polyacrylamide gel electrophoresis.
Immunohistochemistry
Mouse brain and spinal cord were immersion fixed in 10% buffered formaldehyde-saline, embedded in paraffin wax and sections cut at 3-4 mm nominal thickness. Antigen retrieval was performed with citrate buffer or proteases depending on the antibody. 
Quantification of pathological findings
Quantification was performed blinded on four mice per genotype (CHMP2B wild-type , CHMP2B intron 5 and non-transgenics) at 6, 12 and 18 months of age using brightfield images taken as described earlier.
For p62 inclusion quantification in brain, three Â 40 images (21 069 mm 2 per image) were taken in the thalamus and cortex and six in the corpus callosum and inclusions counted using the touch count tool in analySIS imaging software (Olympus). For p62 inclusion quantification in spinal cord, motor neurons were identified by size and location and scored as either inclusion positive or negative. At least 50 motor neurons were counted in at least 3 lumbar spinal cord sections per mouse. For quantification of GFAP and Iba1 staining, 6-10 Â 10 images (335 628 mm 2 per image) were taken in the cortex and corpus callopsum and one in the thalamus. The same threshold for GFAP staining was applied to all images using Volocity Õ image analysis software (Perkin Elmer) and the area covered by GFAP immunoreactivity quantified. Activation of Iba1-positive microglia was performed by scoring each image from 1-4 (1 = ramified, 2 = reactive, 3 = amoeboid and 4 = phagocytic) ( Supplementary Fig. 3 ), as previously described (Ahmed et al., 2010) , and taking the average of all images per region. Statistical testing was performed with Graphpad Prism 5 software using a two-way ANOVA and post hoc Bonferroni test analysing selected pairs of columns.
Electron microscopy
Mice were perfused with 3% glutaraldehyde in phosphate buffer and brains removed and post-fixed overnight in the same fixative. Brains were treated with 1% osmium tetroxide for 3 h at 4 C and embedded in Araldite Õ CY212 resin. Ultrathin sections (70 mm) were stained with lead citrate and uranyl acetate and digital images taken on a Phillips CM10 electron microscope with a Megaview III digital camera (Olympus).
Results
Generation of CHMP2B transgenic mice and Chmp2b knockout mice
We generated two independent lines expressing human CHMP2B intron 5 (designated Tg153 and Tg156) and two lines expressing human CHMP2B wild-type (Tg167 and Tg168) under the control of the hamster prion protein gene promoter (Fig. 1A) . To determine protein expression levels of each line, we generated polyclonal antibodies directed against full-length recombinant CHMP2B that were able to detect both CHMP2B wild-type and CHMP2B intron 5 . Both CHMP2B intron 5 lines expressed the protein at levels similar to endogenous mouse CHMP2B, while both CHMP2B wild-type lines expressed at levels higher than endogenous mouse CHMP2B (Fig. 1C) . We focused our analyses on Tg153 and Tg168 for which transgenic human CHMP2B protein levels were 0.9 AE 0.1 (SEM) and 6.6 AE 0.4 (SEM), respectively relative to mouse CHMP2B (Fig. 1F) . Transgene RNA levels were $3-fold higher than endogenous mouse Chmp2b RNA levels for both Tg153 and Tg168 (Fig. 1E) . We generated homozygous Chmp2b knockout mice (Chmp2b À/À ) from a BayGenomics embryonic stem cell line with a genetrap insertion in intron 2 of Chmp2b (Fig. 1B) . Analysis of protein levels showed that the knockout is incomplete intron 5 mice, (Fig. 1D) , leading to an 84% reduction in CHMP2B levels (Fig. 1G ).
Reduced survival in CHMP2B intron 5 mice
Kaplan-Meier survival analysis showed that CHMP2B intron 5 mice had decreased survival when compared with CHMP2B
wild-type mice and non-transgenic controls (P = 0.001) (Fig. 2A) . Chmp2b À/À mice did not have significantly different survival to controls (Fig. 2B) .
Progressive inclusion formation in CHMP2B intron 5 mice CHMP2B intron 5 mice developed an age-dependent accumulation of p62-positive inclusions that were abundant by 18 months of age and were observed in a range of brain regions including frontal cortex, brainstem, thalamus and corpus callosum, as well as in motor neurons in the spinal cord (Fig. 3 ). This pattern of pathology is likely to reflect the distribution of transgene expression driven by the hamster prion protein gene promoter. Large neuronal inclusions (examples are indicated by black arrows in Figs 3 and 5) as well as dot and thread-like inclusions in the neuropil (examples are indicated by white arrows in Fig. 5 ) were observed. We compared 18-month-old transgenic mice to 24-month-old Chmp2b À/À mice to ensure that we were not missing age-related pathology in the knockouts. Inclusions were not observed in any brain region in Chmp2b À/ À mice, CHMP2B wild-type transgenics or in non-transgenics (Fig. 3 ), but were observed in our second CHMP2B intron 5 line ( Supplementary Fig. 1 ). This suggests that inclusion formation is a specific effect of mutant CHMP2B. We next defined the extent and localization of inclusion pathology in 18-month-old CHMP2B intron 5 brain and spinal cord (Fig.   4 ). The spinal cord showed widespread inclusions throughout the grey matter, with inclusions generally less frequent in the white matter other than a concentration in the dorsal corticospinal tract (Fig. 4B) . The brain also showed widespread inclusion pathology which we scored as mild, moderate or severe (Fig. 4A) . We then chose the cortex, corpus callosum and thalamus, which showed mild, moderate and severe inclusion pathology respectively, for quantification of inclusion number at 6, 12 and 18 months of age. Inclusions were observed in each area at 6 months and increased with age, with inclusions more frequent in the thalamus and corpus callosum than the cortex (Figs 5 and 6) . Quantification of the percentage of motor neurons containing inclusions at 6, 12 and 18 months of age showed 5% of motor neurons contained inclusions at 6 months of age, rising to 30% at 18 months of age (Fig. 6 ). The formation of insoluble inclusions containing p62 was confirmed using immunoblotting of sarkosyl insoluble fractions from the transgenic mouse brains. The level of p62 in the insoluble fraction was increased in CHMP2B intron 5 mice when compared to CHMP2B wild-type mice and non-transgenics (Fig. 7) .
Further immunohistochemical analysis of the inclusions showed that they were also positive for ubiquitin but negative for TDP-43 and FUS (Fig. 8) , mimicking the composition of inclusions in CHMP2B mutation patient brains (Holm et al., 2007 (Holm et al., , 2009 ).
To determine whether CHMP2B was also present in the inclusions we generated antibodies against full-length recombinant CHMP2B. CHMP2B was present in a minority of the inclusions (Fig. 8) , specifically large inclusions rather than the dot and thread-like inclusions.
Age-related gliosis in CHMP2B and non-transgenic mice. Progressive activation of both astrocytes and microglia was observed specifically in CHMP2B intron 5 mouse brains ( Fig. 9 and Supplementary Fig. 2 ). Quantification of GFAP immunoreactivity in the cortex, thalamus and corpus callosum of CHMP2B intron 5 mouse brain showed no evidence of astrogliosis at 6 months of age, suggesting that astrogliosis occurs after inclusion formation; (A) Inclusion frequency was qualitatively assessed in four 18-month-old CHMP2B intron 5 mouse brains and then scored as mild (yellow), moderate (orange), or severe (red). Mild inclusion pathology is observed throughout the cortex, in the white matter of the cerebellum and in the superior colliculus, other than the superficial layer which has severe pathology. Moderate pathology was observed in the corpus callosum and brainstem, other than occasional axonal tracts in the brainstem which had severe pathology. Severe inclusion pathology was observed in the thalamus. (B) Every inclusion in a representative lumbar spinal cord section was traced onto a schematic with large and small dots indicating the size of the inclusions. Inclusions are abundant throughout the grey matter and less common in the white matter, other than the dorsal corticospinal tract.
however, by 12 months of age both the cortex and thalamus showed proliferation of GFAP-positive astrocytes (Figs 9, 10A and B). The astrogliosis was more marked in the thalamus ( Fig.  10A and B) , mirroring the severity of inclusion formation. Astrocytes were abundant in the corpus callosum in mice of all genotypes so no differences were observed (data not shown).
We also quantified the activation of Iba1-positive microglia, classifying them in increasing order of activation as either ramified, reactive, amoeboid or phagocytic ( Supplementary Fig. 3 ) as previously described (Ahmed et al., 2010) . Reactive microglia were observed in the thalamus of CHMP2B intron 5 mice at 6 months of age, and progressed to amoeboid by 12 months and phagocytic by 18 months of age (Figs 9 and 10D ). Microgliosis was also observed in the cortex and corpus callosum, but was less pronounced, with some reactive microglia observed at 6 and 12 months, but not consistently until 18 months of age ( Fig. 10C and E). The appearance of reactive microglia at 6 months of age in the thalamus indicates that microgliosis occurs prior to astrogliosis in this brain region. The presence of marked gliosis shows that CHMP2B intron 5 expression can lead to severe pathological changes reminiscent of those in human patients.
Progressive axonopathy in CHMP2B intron 5 mice
Due to the presence of inclusions in the corpus callosum, we further investigated axonal pathology using amyloid precursor protein staining, which is a sensitive marker of axonal damage (Coleman, 2005) . Amyloid precursor protein staining revealed axonal swellings in the corpus callosum of CHMP2B intron 5 mice but not in CHMP2B wild-type , Chmp2b À/À knockout or non-transgenic mice (Fig. 11) . The swellings were apparent at 6 months and increased with age. Electron microscopy showed that the swellings contained an accumulation of mitochondria and vesicles from endolysosomal and autophagy pathways (Fig. 12) . We also observed accumulation of the presynaptic marker synaptophysin in 18-month-old CHMP2B intron 5 thalamus ( Supplementary Fig. 4 ), further suggestive of axonal dysfunction. These findings suggest that early axonal impairment could contribute to neuronal dysfunction in FTLD caused by CHMP2B mutations.
Discussion
We have generated the first mouse model of CHMP2B-induced neurodegeneration and show that expression of mutant CHMP2B intron 5 leads to striking neurodegenerative changes that are not observed in CHMP2B wild-type transgenics or Chmp2b knockout mice. Importantly, the neurodegenerative changes were very similar to those observed in patients with CHMP2B mutation, particularly the formation of p62-and ubiquitin-positive, but TDP-43-and FUS-negative neuronal inclusions. These data also show that the overt neuropathology observed in patients with CHMP2B mutation is caused by toxic gain of function of CHMP2B intron 5 and not loss of function of CHMP2B or a dominant negative effect on CHMP2B function. As $15% of mouse CHMP2B protein levels remain in our Chmp2b À/À line, we cannot completely rule out the possibility that loss of function contributes to neuropathological changes, however, this seems unlikely as the protein level is well below the 50% reduction observed in patients and no neuropathological changes were observed up to 2 years of age, which is towards the maximal lifespan of a laboratory mouse (only 30% of both controls and knockouts survived to 2 years of age). Another possibility is that loss of function of CHMP2B contributes to other aspects of the disease phenotype. Such a phenomenon has been described for spinocerebellar ataxia type 1 (SCA1), which is caused by an expanded CAG repeat in the ATXN1 gene. Loss of Atxn1 in mice does not lead to neurodegenerative changes (Matilla et al., 1998) while expression of the expanded repeat does (Watase et al., 2002) . However, it has now been demonstrated that partial loss of function of Atxn1 contributes to other features of the disease including behavioural changes and transcriptional dysregulation ( , CHMP2B wild-type and non-transgenic brain and spinal cord. Blind counts of p62 inclusion number were performed at 6, 12 and 18 months of age in the cortex, corpus callosum, thalamus and spinal cord of non-transgenic (non-Tg), CHMP2B intron 5 and CHMP2B wild-type mice (n = 4 per genotype). Inclusions are significantly increased in CHMP2B intron 5 mice and increase with age. *P 5 0.05, **P 5 0.01, ***P 5 0.001, ****P 5 0.0001, two-way ANOVA with
Bonferroni post-test. We showed that inclusion and glial pathology is widespread and progressive in CHMP2B intron 5 brain and spinal cord. This distribution of pathology will be influenced by the pattern of gene expression driven by the hamster prion protein gene promoter so is unlikely to be identical to that seen in patients. We observed cortical pathology, as well as abundant pathology in the thalamus, which is consistent with thalamic expression in other transgenics using the hamster prion protein gene promoter (Asante et al., 2002 (Asante et al., , 2006 . The other striking pathology in CHMP2B intron 5
mice was the presence of axonal swellings, which combined with gliosis and inclusion formation indicate that a neurodegenerative process is occurring. Future investigations to quantify neuron and axon numbers with stereological techniques will be important to address the extent of axon and cell loss. Similar pathological changes have been observed in progranulin knockout mice. Loss of function mutations in progranulin are a relatively common cause of FTLD suggesting knockout mice may be a useful model to investigate disease pathogenesis. Progranulin knockout mice exhibit progressive accumulation of ubiquitinpositive inclusions and progressive activation of microglia and astrocytes (Ahmed et al., 2010; Yin et al., 2010a, b; Petkau et al., 2011; Ghoshal et al., 2012) . This pathology was observed in the cortex, but to a greater extent in the hippocampus, brainstem and thalamus (Ahmed et al., 2010) . This pattern was suggested to reflect brain areas with high levels of progranulin expression that became particularly affected after progranulin deletion (Ahmed et al., 2010) . The neuronal ubiquitin-positive inclusions were described as granular and cytoplasmic (Ahmed et al., 2010; Petkau et al., 2011; Ghoshal et al., 2012) so appear morphologically distinct from the large dense neuronal aggregates that we observed in CHMP2B intron 5 mice. However, as both CHMP2B
and progranulin have been implicated in lysosomal degradation showed increased astrogliosis at 12 and 18 months of age in the cortex and thalamus, but were not significantly different to controls at 6 months of age. No difference in astrogliosis was observed at any age in the corpus callosum as astrocytes were abundant in all genotypes (data not shown). CHMP2B intron 5 mice showed significantly increased microgliosis at 6, 12 and 18 months in the thalamus and at 18 months only in the cortex and corpus callosum. *P 5 0.05, **P 5 0.01, ***P 5 0.001, ****P 5 0.0001, two-way ANOVA with Bonferroni post-test.
pathways (Filimonenko et al., 2007; Hu et al., 2010; Urwin et al., 2010a) , it will be interesting to determine whether they share overlapping disease mechanisms. The generation of the first CHMP2B intron 5 mouse model provides new insight into the mechanisms by which mutant CHMP2B leads to neuronal dysfunction in vivo. CHMP2B is part of the ESCRT-III complex, which has been implicated in autophagic and endosomal trafficking to the lysosome (Katzmann et al., 2002; Rusten and Stenmark, 2009) . It has been shown that expression of CHMP2B intron 5 in cell culture can lead to the formation of ubiquitin-and p62-positive inclusions (Filimonenko et al., 2007; Lee et al., 2007) mimicking the data described here in transgenic mice. The formation of inclusions is likely to be due to impaired lysosomal degradation through the autophagy and endosomelysosome pathways (Filimonenko et al., 2007; Lee et al., 2007; Metcalf and Isaacs, 2010; Urwin et al., 2010a) . How impairment of such central degradative processes leads to selective neuronal loss remains unresolved. One possibility is that CHMP2B is required for the degradation of specific substrates that are vital for neuronal function. For example, it has been shown that levels of the Toll receptor are increased in Drosophila when CHMP2B intron 5 is overexpressed leading to the suggestion Figure 11 Progressive axonal damage in CHMP2B intron 5 mice. Amyloid precursor protein staining revealed numerous axonal swellings within the corpus callosum at both 6 and 12 months of age that were not present in CHMP2B wild-type , non-transgenic or Chmp2b À/À mice. Scale bar = 160 mm.
Neurodegenerative changes in CHMP2B mutant mice that altered Toll-like receptor signalling may play a role in CHMP2B-induced neurodegeneration (Ahmad et al., 2009 ). An impairment of neuron-specific endosomal trafficking functions could also provide cell-type specificity. Recent data show that CHMP2B intron 5 can affect dendritic spine morphology in primary neurons (Belly et al., 2010) and combined with evidence that other ESCRT proteins can promote neurotransmitter receptor trafficking to lysosomes (Kantamneni et al., 2009) , it is possible that dendritic neurotransmitter levels could be altered by mutant CHMP2B and contribute to neuronal dysfunction. Our identification of early and progressive axonal swellings in CHMP2B intron 5 mice raises the possibility that axonal transport could also be affected. Recruitment of Rab7 was shown to be an important step for rendering an endosome capable of long range retrograde axonal trafficking (Deinhardt et al., 2006) . We have previously shown that Rab7 recruitment to endosomes is impaired by CHMP2B intron 5 (Urwin et al., 2010a) , suggesting a potential mechanism for impaired axonal transport. Altered axonal transport has been implicated in a range of neurodegenerative diseases and further deciphering the mechanisms and specific cargoes affected is an important unanswered question (Wu et al., 2009; Perlson et al., 2010) . Electron microscopy showed that at 12 months of age axonal swellings contained mitochondria and vesicles from the endo-lysosomal and autophagy pathways. Axonal accumulations of such vesicles have also been observed in other neurodegenerative conditions including Lurcher mice, which suffer an excitotoxic Purkinje cell loss (Wang et al., 2006) , and in dystrophic neurites in Alzheimer's disease (Nixon et al., 2005) . Axonal swellings in motor neuron disease have been described to contain densely packed neurofilaments (Delisle and Carpenter, 1984; Tu et al., 1996; Laird et al., 2008) , while both neurofilament and vesicle-laden axonal swellings have been observed in mutant tau mouse models (Spittaels et al., 1999; Probst et al., 2000; Lin et al., 2003) . Further work will be required to determine whether the contents of the swellings change over time and if this is related to the neurodegenerative mechanism.
The exact role of mutant CHMP2B in inclusion formation will also require further investigation. Our observation that it is only present in larger inclusions suggests that another protein is accumulating as a result of CHMP2B mutation. Identification of the accumulating protein will be an important step towards defining the full complement of aggregating proteins in FTLD, and the CHMP2B intron 5 mice will be a valuable tool for this endeavour.
In this context, it is intriguing that the recently discovered FTLDand motor neuron disease-causing repeat expansion in C9ORF72 (Dejesus-Hernandez et al., 2011; Renton et al., 2011) leads to abundant p62-and ubiquitin-positive inclusions that are also negative for TDP-43 and FUS (Al Sarraj et al., 2011; Murray et al., 2011) . It will be important to determine whether the same protein is accumulating in C9ORF72 and CHMP2B mutation cases. In conclusion, the development of a mouse model that faithfully recapitulates aspects of the pathology observed in CHMP2B mutation patients has provided new insight into the mechanism of CHMP2B-induced neuronal dysfunction in vivo, and is an important new model for further dissecting this degenerative pathway. 
